ImmunoPrecise Antibodies (IPA)
(Delayed Data from NSDQ)
$1.89 USD
+0.08 (4.42%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.89 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IPA 1.89 +0.08(4.42%)
Will IPA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPA
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates
ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock?
IPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates
P3 Health Partners Inc. (PIII) Reports Q4 Loss, Lags Revenue Estimates
Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates
Other News for IPA
ImmunoPrecise Antibodies divests Netherlands facilities to AVS Bio
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate ...
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and ...
ImmunoPrecise Antibodies Ltd (IPA) Q4 2025 Earnings Call Highlights: Record Revenue and ...
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript